M.B. Executive Vice President, Chief Scientific Officer · Sarepta Therapeutics, Inc. (SRPT)

Gilmore O'Neill

A named executive officer of Sarepta Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$3,790,049

Salary $583,277Stock awards $766,949

FY2019: $5,168,110

4th of 8 named executive officers at Sarepta Therapeutics by FY2020 total.

8 named officers on file for Sarepta Therapeutics, FY2020

Gilmore O'Neill’s pay file — $29

  • 3 fiscal years of pay, line by line
  • SRPT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sarepta Therapeutics’s whole pay program stands against its peers

  • Sarepta Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SRPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 20, 2021 (DEF 14A).

Free

Get Gilmore O'Neill’s full pay file as a PDF — free

More than this page: up to 10 years of Gilmore’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Gilmore O'Neill compensation by year

Sarepta Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Sarepta Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020
Salary$310,962$563,962$583,277
Bonus$0$0$0
Stock awards$1,154,760$0$766,949
Option awards$4,768,050$4,234,786$2,131,159
Non-equity incentive$213,354$354,063$293,164
Pension and deferred compensation$0$0$0
All other$2,050$15,300$15,500
Total$6,449,176$5,168,110$3,790,049

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 20, 2021, accession 0001564590-21-019631, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sarepta Therapeutics, Inc. filed document, accession 0001564590-21-019631. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2021.

$6.4M
$5.2M
$3.8M
FY18
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU3,750$337,688—
RSU1,675$150,834—
OPTION58,853—$87.11
OPTION12,500—$96.23
OPTION16,489—$145.48
OPTION19,433—$114.47

Per the Outstanding Equity Awards at Fiscal Year-End table in Sarepta Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Sarepta Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Louise Rodino-KlapacExecutive Vice President, Chief Scientific Officer$7,269,509
David HowtonExecutive Vice President, General Counsel and Corporate Secretary$5,703,078
Ian EstepanExecutive Vice President, Chief Financial Officer$5,177,681
Gilmore O'Neill · this pageM.B. Executive Vice President, Chief Scientific Officer$3,790,049
Sandesh MahatmeExecutive Vice President, Chief Financial Officer and Chief Business Officer$3,364,021
Douglas IngramPresident and Chief Executive Officer$1,291,947
Joseph BraticaVice President, Corporate Controller$911,887
William CiambroneExecutive Vice President, Technical Operations$679,938

The full Sarepta Therapeutics compensation record

free company brief

This page is one person within Sarepta Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Sarepta Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sarepta Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gilmore O'Neill's compensation dossier · One-time report. No refunds.